COVID-19

Wondering what you can do to help end the acute phase of the pandemic? Go Give One – is giving everyone everywhere a chance to play their part.

Mastercard, a long-standing partner of Gavi, recently committed US$ 28 million to the Gavi COVAX AMC, to ensure vaccines are accessible to those that needed them the most, no matter where they live. Vaccines Work spoke to Michael Froman to learn why this is a priority and why the private sector needs to be involved in the COVID-19 response.

The pandemic turned our normal ways of working upside down, but there are several ways in which the new normal could bring improvements in the way we fight disease.

Antibody therapy reduces COVID-19 fatalities by a fifth, but remains inaccessible to many countries.

People who are afraid of needles are twice as likely to be vaccine hesitant, new research shows.

Scientists around the world are working faster than ever to develop and produce vaccines that can stop the spread of COVID-19. Since the emergence of this novel coronavirus in December 2019, more than a dozen vaccines have started to be rolled out. Here is an at-a-glance overview of those vaccines and recent developments of those vaccine candidates in clinical trials.

There are now 17 COVID-19 vaccines approved for emergency use, but as the virus continues to evolve, here is why we can’t pull the plug on research into new vaccines and therapeutics.

Although the coronavirus doesn’t cause disease and death in children as much as it does in adults, many children around the world are vulnerable to the collateral damage wreaked by the pandemic.

A new paper suggests that plant- and fish-based diets lessen the chance of developing severe symptoms – but hold off from becoming vegetarian or pescatarian for now.

The Delta (B.1.617.2) variant of SARS CoV-2 was first detected in India and is rapidly spreading around the world. Here’s what we know about it so far.